Efficacy of lamotrigine in institutionalized, developmentally disabled patients with epilepsy: A retrospective evaluation

Abstract

The paper evaluates the efficacy of the newer anticonvulsant lamotrigine in a developmentally disabled patient population. A retrospective evaluation was done at two institutional centres to assess adjunctive lamotrigine (Lamictal®) efficacy in a developmentally disabled population. Mean seizure frequency was compared between a 2-month pre-lamotrigine baseline period and a 2-month treatment period. A 3-month lamotrigine titration phase occurred between baseline and treatment periods. Seizure frequency data was obtained from standardized, daily seizure records. Adverse effect data was obtained from medical and nursing notes. An intent to treat analysis was performed. Data were analysed using Student's t-test for paired data. We evaluated 44 centre residents (25 male, 19 female, average age 33 ± 11 years). Mean lamotrigine dose was 272 ± 133 mg per day. A significant reduction in seizure frequency was noted. Seizure frequency (all seizures) was 10.1 ± 11.2 during the baseline period vs. 5.8 ± 7.9 seizures per month during the treatment period (P = 0.002). Thirty-two percent of patients (n = 14) had greater than a 75% reduction in seizure frequency. Twenty-three percent of patients (n = 10) had a 50-74% seizure reduction. Twenty-five percent of patients (n = 11) had less than a 50% reduction in seizures, while 20% (n = 9) had an increase in seizures. A significant reduction of 48% in generalized seizures (9.5 ± 11.6 vs. 4.9 ± 6.5 seizures per month, P = 0.013) was noted. Reductions in partial seizure frequency of 48% (7.9 ± 10 vs. 4 ± 6.6 seizures per month, P = 0.16) as well as in mixed-type seizures (19.9 ± 9.3 was vs. 15 ± 12.1 seizures per month, P = 0.11) were also seen; however, these changes did not reach significance. Overall, lamotrigine was well tolerated by the subject population. Adjunctive treatment with lamotrigine appears to be an efficacious and well-tolerated treatment for seizures in a significant percentage of developmentally disabled patients with epilepsy. (C) 2000 BEA Trading Ltd.